Skip to main content
Erschienen in: Clinical Pharmacokinetics 1/2006

01.01.2006 | Review Article

Mass Balance Studies, with a Focus on Anticancer Drugs

verfasst von: Dr Jan H. Beumer, Jos H. Beijnen, Jan H. M. Schellens

Erschienen in: Clinical Pharmacokinetics | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

The importance of in-depth knowledge about the pharmacokinetics of a drug is evident because pharmacokinetic behaviour may correlate with activity and toxicity. The most elaborate pharmacokinetic investigation is a so-called mass balance study employing a radioactive tracer. A mass balance study investigates the plasma pharmacokinetics and excretion of both the unchanged drug and the total radioactivity (drug and metabolites), and allows elucidation of the metabolic fate of a drug. The main objective is the maximum recovery of the radioactive dose in urine and faeces. However, there is little concrete guidance on how to perform or assess such a mass balance study. Based on a critical review of the available literature and regulation, we discuss the design, conduct and evaluation of mass balance studies. The study must be preceded by pre-clinical studies to optimise the design. Compliance with available regulation (US FDA is more specific than European guidelines), choice of radioisotope (tritium may be lost and is consequently used less often), selection of subjects and safe administration of a relevant dose are critical. The drug (both the labelled and the non-labelled portion of the dose) must be prepared, characterised and administered, and the biological samples must be collected and analysed properly to obtain reliable and meaningful results. A recent development is the use of highly sensitive accelerator mass spectrometry for 14C-detection, which allows the use of much lower amounts of radioactivity. Calculating the mass balance requires quantification of any possible losses of radioactivity during the study, e.g. during administration (adsorption to tubing). Total recovery should be at least 90% of the administered dose. A lower recovery, which is not uncommon, must be explained by biological factors such as a long decay half-life, irreversible binding to tissue components, or loss through expiration. The extent and relevance of metabolism is determined by comparing the pharmacokinetics of the unchanged drug and the total radioactivity. Metabolic profiling supplements existing knowledge of metabolism. We illustrate the important aspects of a mass balance study with literature on anticancer drugs. This review could serve as guidance for future mass balance studies.
Literatur
1.
Zurück zum Zitat Center for Drugs and Biologics, Food and Drug Administration, Department of Health and Human Services Center for Drug Evaluation and Research. Guideline for the format and content of the human pharmacokinetics and bioavailability section of an application [online]. Available from URL: http://www.fda.gov/cder/guidance/old071fn.pdf [Accessed 2004 May 3] Center for Drugs and Biologics, Food and Drug Administration, Department of Health and Human Services Center for Drug Evaluation and Research. Guideline for the format and content of the human pharmacokinetics and bioavailability section of an application [online]. Available from URL: http://​www.​fda.​gov/​cder/​guidance/​old071fn.​pdf [Accessed 2004 May 3]
4.
Zurück zum Zitat Center for Drugs and Biologics, Food and Drug Administration, Department of Health and Human Services Center for Drug Evaluation and Research. Guideline for the format and content of the nonclinical pharmacology/toxicology section of an application [online]. Available from URL: http://www.fda.gov/cder/guidance/old032fn.pdf [Accessed 2004 May 3] Center for Drugs and Biologics, Food and Drug Administration, Department of Health and Human Services Center for Drug Evaluation and Research. Guideline for the format and content of the nonclinical pharmacology/toxicology section of an application [online]. Available from URL: http://​www.​fda.​gov/​cder/​guidance/​old032fn.​pdf [Accessed 2004 May 3]
5.
Zurück zum Zitat Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998 Feb; 44(2): 388–400PubMed Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998 Feb; 44(2): 388–400PubMed
9.
Zurück zum Zitat Vodopick H, Hamilton HE, Jackson HL, et al. Metabolic fate of tritiated busulfan in man. J Lab Clin Med 1969 Feb; 73(2): 266–76PubMed Vodopick H, Hamilton HE, Jackson HL, et al. Metabolic fate of tritiated busulfan in man. J Lab Clin Med 1969 Feb; 73(2): 266–76PubMed
10.
Zurück zum Zitat Nadkarni MV, Trams EG, Smith PK. Preliminary studies on the distribution and fate of TEM, TEPA, and myleran in the human. Cancer Res 1959 Aug; 19: 713–8PubMed Nadkarni MV, Trams EG, Smith PK. Preliminary studies on the distribution and fate of TEM, TEPA, and myleran in the human. Cancer Res 1959 Aug; 19: 713–8PubMed
11.
Zurück zum Zitat De Vita VT, Denham C, Davidson JD, et al. The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in man and animals. Clin Pharmacol Ther 1967 Jul; 8(4): 566–77 De Vita VT, Denham C, Davidson JD, et al. The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in man and animals. Clin Pharmacol Ther 1967 Jul; 8(4): 566–77
12.
Zurück zum Zitat McLean A, Woods RL, Catovsky D, et al. Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. Cancer Treat Rev 1979 Jun; 6 Suppl.: 33–42PubMed McLean A, Woods RL, Catovsky D, et al. Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. Cancer Treat Rev 1979 Jun; 6 Suppl.: 33–42PubMed
13.
Zurück zum Zitat Alberts DS, Chang SY, Chen HS, et al. Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. Cancer Treat Rev 1979 Jun; 6 Suppl.: 9–17PubMed Alberts DS, Chang SY, Chen HS, et al. Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. Cancer Treat Rev 1979 Jun; 6 Suppl.: 9–17PubMed
14.
Zurück zum Zitat Creaven PJ, Allen LM, Alford DA, et al. Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 1974 Jul; 16(1): 77–86PubMed Creaven PJ, Allen LM, Alford DA, et al. Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 1974 Jul; 16(1): 77–86PubMed
15.
Zurück zum Zitat Alberts DS, Chang SY, Chen HS, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther 1979 Jul; 26(1): 73–80PubMed Alberts DS, Chang SY, Chen HS, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther 1979 Jul; 26(1): 73–80PubMed
16.
Zurück zum Zitat Tattersall MH, Jarman M, Newlands ES, et al. Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 1978 May; 14(5): 507–13PubMed Tattersall MH, Jarman M, Newlands ES, et al. Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 1978 May; 14(5): 507–13PubMed
17.
Zurück zum Zitat Maller RK, McIver FA, Heidelberger C. Studies on OPSPA: III. Distribution and excretion of radioactivity following administration of OPSPA-C14 and OPSPA-P32 to humans. Cancer Res 1957 May; 17(4): 291–5PubMed Maller RK, McIver FA, Heidelberger C. Studies on OPSPA: III. Distribution and excretion of radioactivity following administration of OPSPA-C14 and OPSPA-P32 to humans. Cancer Res 1957 May; 17(4): 291–5PubMed
18.
Zurück zum Zitat Malier RK, Heidelberger C. Studies on OPSPA: IV. Metabolism of OPSPA in the rat and human. Cancer Res 1957 May; 17(4): 296–301 Malier RK, Heidelberger C. Studies on OPSPA: IV. Metabolism of OPSPA in the rat and human. Cancer Res 1957 May; 17(4): 296–301
19.
Zurück zum Zitat Gaver RC, Deeb G, Pittman KA, et al. Disposition of orally administered 14C-prednimustine in cancer patients. Cancer Chemother Pharmacol 1983; 11(3): 139–43PubMed Gaver RC, Deeb G, Pittman KA, et al. Disposition of orally administered 14C-prednimustine in cancer patients. Cancer Chemother Pharmacol 1983; 11(3): 139–43PubMed
20.
Zurück zum Zitat Schwartz DE, Bollag W, Obrecht P. Distribution and excretion studies of procarbazine in animals and man. Arzneimittel Forschung 1967 Nov; 17(11): 1389–93PubMed Schwartz DE, Bollag W, Obrecht P. Distribution and excretion studies of procarbazine in animals and man. Arzneimittel Forschung 1967 Nov; 17(11): 1389–93PubMed
21.
Zurück zum Zitat Adolphe AB, Glasofer ED, Troetel WM, et al. Fate of streptozotocin (NSC-85998) in patients with advanced cancer. Cancer Chemother Rep 1975 May; 59(3): 547–56PubMed Adolphe AB, Glasofer ED, Troetel WM, et al. Fate of streptozotocin (NSC-85998) in patients with advanced cancer. Cancer Chemother Rep 1975 May; 59(3): 547–56PubMed
22.
Zurück zum Zitat Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999 Feb; 5(2): 309–17PubMed Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999 Feb; 5(2): 309–17PubMed
23.
Zurück zum Zitat Forshell GP, Muntzing J, Ek A, et al. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer. Invest Urol 1976 Sep; 14(2): 128–31PubMed Forshell GP, Muntzing J, Ek A, et al. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer. Invest Urol 1976 Sep; 14(2): 128–31PubMed
24.
Zurück zum Zitat Hall SW, Friedman J, Legha SS, et al. Human pharmacokinetics of a new acridine derivative, 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). Cancer Res 1983 Jul; 43(7): 3422–6PubMed Hall SW, Friedman J, Legha SS, et al. Human pharmacokinetics of a new acridine derivative, 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). Cancer Res 1983 Jul; 43(7): 3422–6PubMed
25.
Zurück zum Zitat Oken MM, Crooke ST, Elson MK, et al. Pharmacokinetics of bleomycin after im administration in man. Cancer Treat Rep 1981 May; 65(5–6): 485–9PubMed Oken MM, Crooke ST, Elson MK, et al. Pharmacokinetics of bleomycin after im administration in man. Cancer Treat Rep 1981 May; 65(5–6): 485–9PubMed
26.
Zurück zum Zitat Tattersall MH, Sodergren JE, Dengupta SK, et al. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 1975 Jun; 17(6): 701–8PubMed Tattersall MH, Sodergren JE, Dengupta SK, et al. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 1975 Jun; 17(6): 701–8PubMed
27.
Zurück zum Zitat Di Fronzo G, Bonadonna G. Preliminary studies on the distribution and excretion of tritiated daunomycin in men [in Italian]. Tumori 1969 Sep; 55(5): 263–75PubMed Di Fronzo G, Bonadonna G. Preliminary studies on the distribution and excretion of tritiated daunomycin in men [in Italian]. Tumori 1969 Sep; 55(5): 263–75PubMed
28.
Zurück zum Zitat Di Fronzo G, Bonadonna G. Distribution of tritiated daunomycin in man by a simplified method. Rev Eur Etud Clin Biol 1970 Mar; 15(3): 314–20PubMed Di Fronzo G, Bonadonna G. Distribution of tritiated daunomycin in man by a simplified method. Rev Eur Etud Clin Biol 1970 Mar; 15(3): 314–20PubMed
29.
Zurück zum Zitat Di Fronzo G, Lenaz L, Bonadonna G. Distribution and excretion of adriamycin in man. Biomedicine 1973 Apr; 19(4): 169–71 Di Fronzo G, Lenaz L, Bonadonna G. Distribution and excretion of adriamycin in man. Biomedicine 1973 Apr; 19(4): 169–71
30.
Zurück zum Zitat Carnaggi CM, Stracchi E, Comparsi R, et al. Biliary excretion and pharmacokinetics of 4′epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol 1986; 18(1): 47–50 Carnaggi CM, Stracchi E, Comparsi R, et al. Biliary excretion and pharmacokinetics of 4′epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol 1986; 18(1): 47–50
31.
Zurück zum Zitat Joshi AS, Pieniaszek HJ, Vokes EE, et al. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab Dispos 2001 Feb; 29(2): 96–9PubMed Joshi AS, Pieniaszek HJ, Vokes EE, et al. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab Dispos 2001 Feb; 29(2): 96–9PubMed
32.
Zurück zum Zitat Alberts DS, Peng YM, Leigh S, et al. Disposition of mitoxantrone in cancer patients. Cancer Res 1985 Apr; 45(4): 1879–84PubMed Alberts DS, Peng YM, Leigh S, et al. Disposition of mitoxantrone in cancer patients. Cancer Res 1985 Apr; 45(4): 1879–84PubMed
33.
Zurück zum Zitat Alberts DS, Peng YM, Leigh S, et al. Disposition of mitoxantrone in patients. Cancer Treat Rev 1983 Dec; 10 Suppl. B: 23–7PubMed Alberts DS, Peng YM, Leigh S, et al. Disposition of mitoxantrone in patients. Cancer Treat Rev 1983 Dec; 10 Suppl. B: 23–7PubMed
34.
Zurück zum Zitat John BA, Brodie RR, Baldock GA, et al. Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica 2002 Aug; 32(8): 699–713PubMed John BA, Brodie RR, Baldock GA, et al. Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica 2002 Aug; 32(8): 699–713PubMed
35.
Zurück zum Zitat Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (I.C.I. 46,474): II. In female patients. Xenobiotica 1973 Nov; 3(11): 711–4PubMed Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (I.C.I. 46,474): II. In female patients. Xenobiotica 1973 Nov; 3(11): 711–4PubMed
36.
Zurück zum Zitat Dalrymple PD, Nicholls PJ. Metabolism profiles and excretion of 14C-aminoglutethimide in several animal species and man. Xenobiotica 1988 Jan; 18(1): 75–81PubMed Dalrymple PD, Nicholls PJ. Metabolism profiles and excretion of 14C-aminoglutethimide in several animal species and man. Xenobiotica 1988 Jan; 18(1): 75–81PubMed
37.
Zurück zum Zitat Lonning PE, Geisler J, Johannessen DC, et al. Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Mol Biol 2001 Apr; 77(1): 39–47PubMed Lonning PE, Geisler J, Johannessen DC, et al. Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Mol Biol 2001 Apr; 77(1): 39–47PubMed
38.
Zurück zum Zitat Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001 Jul; 22(5): 191–7PubMed Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001 Jul; 22(5): 191–7PubMed
39.
Zurück zum Zitat Verhoeven CH, Gloudemans RH, Peeters PA, et al. Excretion and metabolism of desogestrel in healthy postmenopausal women. J Steroid Biochem Mol Biol 2001 Nov; 78(5): 471–80PubMed Verhoeven CH, Gloudemans RH, Peeters PA, et al. Excretion and metabolism of desogestrel in healthy postmenopausal women. J Steroid Biochem Mol Biol 2001 Nov; 78(5): 471–80PubMed
40.
Zurück zum Zitat Viinikka L, Ylikorkala O, Vihko R, et al. Metabolism of a new synthetic progestagen, Org 2969, in female volunteers: the distribution and excretion of radioactivity after an oral dose of the labelled drug. Acta Endocrinol (Copenh) 1980 Mar; 93(3): 375–9 Viinikka L, Ylikorkala O, Vihko R, et al. Metabolism of a new synthetic progestagen, Org 2969, in female volunteers: the distribution and excretion of radioactivity after an oral dose of the labelled drug. Acta Endocrinol (Copenh) 1980 Mar; 93(3): 375–9
41.
Zurück zum Zitat Verhoeven CH, Gloudemans RH, Groothuis GM, et al. Excretion balance and metabolism of the progestagen Org 30659 in healthy postmenopausal women. J Steroid Biochem Mol Biol 2000 May; 73(1–2): 39–48PubMed Verhoeven CH, Gloudemans RH, Groothuis GM, et al. Excretion balance and metabolism of the progestagen Org 30659 in healthy postmenopausal women. J Steroid Biochem Mol Biol 2000 May; 73(1–2): 39–48PubMed
42.
Zurück zum Zitat Sandberg AA, Slaunwhite Jr WR. The metabolic fate of C14-progesterone in human subjects. J Clin Endocrinol Metab 1958 Mar; 18(3): 253–65PubMed Sandberg AA, Slaunwhite Jr WR. The metabolic fate of C14-progesterone in human subjects. J Clin Endocrinol Metab 1958 Mar; 18(3): 253–65PubMed
43.
Zurück zum Zitat Sharma H, Thatcher N, Baer J, et al. Blood clearance of radioactively labelled cis-diammine 1, 1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. Cancer Chemother Pharmacol 1983; 11(1): 5–7PubMed Sharma H, Thatcher N, Baer J, et al. Blood clearance of radioactively labelled cis-diammine 1, 1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. Cancer Chemother Pharmacol 1983; 11(1): 5–7PubMed
44.
Zurück zum Zitat Gaver RC, Colombo N, Green MD, et al. The disposition of carboplatin in ovarian cancer patients. Cancer Chemother Pharmacol 1988; 22(3): 263–70PubMed Gaver RC, Colombo N, Green MD, et al. The disposition of carboplatin in ovarian cancer patients. Cancer Chemother Pharmacol 1988; 22(3): 263–70PubMed
45.
Zurück zum Zitat Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984 Apr; 44(4): 1693–7PubMed Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984 Apr; 44(4): 1693–7PubMed
46.
Zurück zum Zitat Thatcher N, Sharma H, Harrison R, et al. Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. Cancer Chemother Pharmacol 1982; 9(1): 13–6PubMed Thatcher N, Sharma H, Harrison R, et al. Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. Cancer Chemother Pharmacol 1982; 9(1): 13–6PubMed
47.
Zurück zum Zitat Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000 Apr; 6(4): 1205–18PubMed Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000 Apr; 6(4): 1205–18PubMed
48.
Zurück zum Zitat Allen J, Graham MA, Firth J, et al. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer [abstract]. Proc Am Assoc Cancer Res 1998; 39: 159 Allen J, Graham MA, Firth J, et al. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer [abstract]. Proc Am Assoc Cancer Res 1998; 39: 159
49.
Zurück zum Zitat Hamilton L, Elion GB. The fate of 6-mercaptopurine in man. Ann N Y Acad Sci 1954 Dec; 60(2): 304–14PubMed Hamilton L, Elion GB. The fate of 6-mercaptopurine in man. Ann N Y Acad Sci 1954 Dec; 60(2): 304–14PubMed
50.
Zurück zum Zitat Lu K, Benvenuto JA, Bodey GP, et al. Pharmacokinetics and metabolism of beta-2′-deoxythioguanosine and 6-thioguanine in man. Cancer Chemother Pharmacol 1982; 8(1): 119–23PubMed Lu K, Benvenuto JA, Bodey GP, et al. Pharmacokinetics and metabolism of beta-2′-deoxythioguanosine and 6-thioguanine in man. Cancer Chemother Pharmacol 1982; 8(1): 119–23PubMed
51.
Zurück zum Zitat Loo TL, Lu K, Gottlieb JA. Disposition and metabolism of thiopurines: II. Arabinosyl-6-mercaptopurine and ribosyl-6-mercaptopurine. Drug Metab Dispos 1973 Jul; 1(4): 645–52PubMed Loo TL, Lu K, Gottlieb JA. Disposition and metabolism of thiopurines: II. Arabinosyl-6-mercaptopurine and ribosyl-6-mercaptopurine. Drug Metab Dispos 1973 Jul; 1(4): 645–52PubMed
52.
Zurück zum Zitat Hull WE, Port RE, Herrmann R, et al. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 1988 Mar; 48(6): 1680–8PubMed Hull WE, Port RE, Herrmann R, et al. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 1988 Mar; 48(6): 1680–8PubMed
53.
Zurück zum Zitat Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987 Apr; 47(8): 2203–6PubMed Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987 Apr; 47(8): 2203–6PubMed
54.
Zurück zum Zitat Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines: IX. the degradation of 5-fluorouracil-6-C14. J Biol Chem 1960 Feb; 235: 433–7PubMed Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines: IX. the degradation of 5-fluorouracil-6-C14. J Biol Chem 1960 Feb; 235: 433–7PubMed
55.
Zurück zum Zitat Mukherjee KL, Boohar J, Wentland D, et al. Studies on fluorinated pyrimidines XVI: metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients. Cancer Res 1963; 23: 49–66 Mukherjee KL, Boohar J, Wentland D, et al. Studies on fluorinated pyrimidines XVI: metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients. Cancer Res 1963; 23: 49–66
56.
Zurück zum Zitat Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines: III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer Res 1958 Apr; 18(3): 318–28PubMed Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines: III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer Res 1958 Apr; 18(3): 318–28PubMed
57.
Zurück zum Zitat Bernadou J, Armand JP, Lopez A, et al. Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance. Clin Chem 1985 Jun; 31(6): 846–8PubMed Bernadou J, Armand JP, Lopez A, et al. Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance. Clin Chem 1985 Jun; 31(6): 846–8PubMed
58.
Zurück zum Zitat Judson IR, Beale PJ, Trigo JM, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 1999; 17(1): 49–56PubMed Judson IR, Beale PJ, Trigo JM, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 1999; 17(1): 49–56PubMed
59.
Zurück zum Zitat Wan SH, Huffman DH, Azarnoff DL, et al. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res 1974 Feb; 34(2): 392–7PubMed Wan SH, Huffman DH, Azarnoff DL, et al. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res 1974 Feb; 34(2): 392–7PubMed
60.
Zurück zum Zitat Malet-Martino MC, Servin P, Bernadou J, et al. Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry. Invest New Drugs 1987; 5(3): 273–9PubMed Malet-Martino MC, Servin P, Bernadou J, et al. Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry. Invest New Drugs 1987; 5(3): 273–9PubMed
61.
Zurück zum Zitat Benvenuto JA, Lu K, Hall SW, et al. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 1978 Nov; 38(11 Pt 1): 3867–70PubMed Benvenuto JA, Lu K, Hall SW, et al. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 1978 Nov; 38(11 Pt 1): 3867–70PubMed
62.
Zurück zum Zitat Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991 Mar; 9(3): 491–8PubMed Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991 Mar; 9(3): 491–8PubMed
63.
Zurück zum Zitat Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997 Apr; 24 (2 Suppl. 7): S7–2PubMed Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997 Apr; 24 (2 Suppl. 7): S7–2PubMed
64.
Zurück zum Zitat Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drag Metab Dispos 2000 Apr; 28(4): 423–33 Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drag Metab Dispos 2000 Apr; 28(4): 423–33
65.
Zurück zum Zitat Herben VMM, Schoemaker E, Rosing H, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002 Jul; 50(1): 59–64PubMed Herben VMM, Schoemaker E, Rosing H, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002 Jul; 50(1): 59–64PubMed
66.
Zurück zum Zitat Creaven PJ, Allen LM. EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 1975 Aug; 18(2): 221–6PubMed Creaven PJ, Allen LM. EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 1975 Aug; 18(2): 221–6PubMed
67.
Zurück zum Zitat Creaven PJ, Allen LM, Alford DA. The bioavailability in man of ICRF-159 a new oral antineoplastic agent. J Pharm Pharmacol 1975 Dec; 27(12): 914–8PubMed Creaven PJ, Allen LM, Alford DA. The bioavailability in man of ICRF-159 a new oral antineoplastic agent. J Pharm Pharmacol 1975 Dec; 27(12): 914–8PubMed
68.
Zurück zum Zitat Creaven PJ, Allen LM. PTG, a new antineoplastic epipodyphyllotoxin. Clin Pharmacol Ther 1975 Aug; 18(2): 227–33PubMed Creaven PJ, Allen LM. PTG, a new antineoplastic epipodyphyllotoxin. Clin Pharmacol Ther 1975 Aug; 18(2): 227–33PubMed
69.
Zurück zum Zitat de Valeriola D, Brassinne C, Gaillard C. Study of excretion balance, metabolism and protein binding of C14 radiolabeled Taxotere (TXT) (RP56976, NSC628503) in cancer patients [abstract]. Proc Am Assoc Cancer Res 1993; 34: 373 de Valeriola D, Brassinne C, Gaillard C. Study of excretion balance, metabolism and protein binding of C14 radiolabeled Taxotere (TXT) (RP56976, NSC628503) in cancer patients [abstract]. Proc Am Assoc Cancer Res 1993; 34: 373
70.
Zurück zum Zitat Beumer JH, Lappin G, Cohen M, et al. Mass balance study with ixabepilone using accelerator mass spectrometry [abstract]. Proc Am Soc Clin Oncol 2004; 23: 136 Beumer JH, Lappin G, Cohen M, et al. Mass balance study with ixabepilone using accelerator mass spectrometry [abstract]. Proc Am Soc Clin Oncol 2004; 23: 136
71.
Zurück zum Zitat Malingré MM, Schellens JHM, van Tellingen O, et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.V. administration. Anticancer Drags 2000 Nov; 11(10): 813–20 Malingré MM, Schellens JHM, van Tellingen O, et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.V. administration. Anticancer Drags 2000 Nov; 11(10): 813–20
72.
Zurück zum Zitat Walle T, Walle UK, Kumar GN, et al. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 1995 Apr; 23(4): 506–12PubMed Walle T, Walle UK, Kumar GN, et al. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 1995 Apr; 23(4): 506–12PubMed
73.
Zurück zum Zitat Gelderblom H, Verweij J, Brouwer E, et al. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. Drag Metab Dispos 1999 Nov; 27(11): 1300–5 Gelderblom H, Verweij J, Brouwer E, et al. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. Drag Metab Dispos 1999 Nov; 27(11): 1300–5
74.
Zurück zum Zitat Owellen RJ, Hartke CA. The pharmacokinetics of 4-acetyltritium vinblastine in two patients. Cancer Res 1975 Apr; 35(4): 975–80PubMed Owellen RJ, Hartke CA. The pharmacokinetics of 4-acetyltritium vinblastine in two patients. Cancer Res 1975 Apr; 35(4): 975–80PubMed
75.
Zurück zum Zitat Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977 Aug; 37(8 Pt 1): 2597–602PubMed Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977 Aug; 37(8 Pt 1): 2597–602PubMed
76.
Zurück zum Zitat Bender RA, Castle MC, Margileth DA, et al. The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther 1977 Oct; 22(4): 430–5PubMed Bender RA, Castle MC, Margileth DA, et al. The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther 1977 Oct; 22(4): 430–5PubMed
77.
Zurück zum Zitat Bore P, Rahmani R, Van Cantfort J, et al. Pharmacokinetics of a new anticancer drag, navelbine, in patients: comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol 1989; 23(4): 247–51PubMed Bore P, Rahmani R, Van Cantfort J, et al. Pharmacokinetics of a new anticancer drag, navelbine, in patients: comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol 1989; 23(4): 247–51PubMed
78.
Zurück zum Zitat Rahmani R, Zhou XJ, Bore P, et al. Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anticancer Drags 1991 Aug; 2(4): 405–10 Rahmani R, Zhou XJ, Bore P, et al. Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anticancer Drags 1991 Aug; 2(4): 405–10
79.
Zurück zum Zitat Bongard HJ, Pluim D, Rosing H, et al. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drags 2002 Sep; 13(8): 807–14 Bongard HJ, Pluim D, Rosing H, et al. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drags 2002 Sep; 13(8): 807–14
80.
Zurück zum Zitat Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate: II. absorption and excretion in man. Cancer Res 1965 Aug; 25(7): 1018–24PubMed Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate: II. absorption and excretion in man. Cancer Res 1965 Aug; 25(7): 1018–24PubMed
81.
Zurück zum Zitat Beale P, Judson I, Hanwell J, et al. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol 1998; 42(1): 71–6PubMed Beale P, Judson I, Hanwell J, et al. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol 1998; 42(1): 71–6PubMed
82.
Zurück zum Zitat Wedge SR, Laohavinij S, Taylor GA, et al. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza 5, 6, 7, 8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1995 Dec; 1(12): 1479–86PubMed Wedge SR, Laohavinij S, Taylor GA, et al. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza 5, 6, 7, 8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1995 Dec; 1(12): 1479–86PubMed
83.
Zurück zum Zitat Gamer RC, Goris I, Laenen AA, et al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 2002 Jul; 30(7): 823–30 Gamer RC, Goris I, Laenen AA, et al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 2002 Jul; 30(7): 823–30
84.
Zurück zum Zitat Wafelman AR, Hoefnagel CA, Maessen HJ, et al. Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. Eur J Nucl Med 1997 May; 24(5): 544–52PubMed Wafelman AR, Hoefnagel CA, Maessen HJ, et al. Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. Eur J Nucl Med 1997 May; 24(5): 544–52PubMed
85.
Zurück zum Zitat Budavari S. The Merck Index. Whitehouse Station (NJ): Merck & Co. Inc., 1996 Budavari S. The Merck Index. Whitehouse Station (NJ): Merck & Co. Inc., 1996
86.
Zurück zum Zitat Dueker SR, Jones AD, Clifford AJ. Protocol development for biological tracer studies. Adv Exp Med Biol 1998; 445: 363–78PubMed Dueker SR, Jones AD, Clifford AJ. Protocol development for biological tracer studies. Adv Exp Med Biol 1998; 445: 363–78PubMed
87.
Zurück zum Zitat Browne TR, Van Langenhove A, Costello CE, et al. Pharmacokinetic equivalence of stable-isotope-labeled and unlabeled drugs. Phenobarbital in man. J Clin Pharmacol 1982 Jul; 22(7): 309–15PubMed Browne TR, Van Langenhove A, Costello CE, et al. Pharmacokinetic equivalence of stable-isotope-labeled and unlabeled drugs. Phenobarbital in man. J Clin Pharmacol 1982 Jul; 22(7): 309–15PubMed
88.
Zurück zum Zitat Phillips DH, Potter GA, Horton MN, et al. Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 1994 Aug; 15(8): 1487–92PubMed Phillips DH, Potter GA, Horton MN, et al. Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 1994 Aug; 15(8): 1487–92PubMed
89.
Zurück zum Zitat Dalvie D. Recent advances in the applications of radioisotopes in drag metabolism, toxicology and pharmacokinetics. Curr Pharm Des 2000 Jul; 6(10): 1009–28PubMed Dalvie D. Recent advances in the applications of radioisotopes in drag metabolism, toxicology and pharmacokinetics. Curr Pharm Des 2000 Jul; 6(10): 1009–28PubMed
90.
Zurück zum Zitat Lenz EM, Wilson ID, Wright B, et al. A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. J Pharm Biomed Anal 2002 Apr; 28(1): 31–43PubMed Lenz EM, Wilson ID, Wright B, et al. A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. J Pharm Biomed Anal 2002 Apr; 28(1): 31–43PubMed
91.
Zurück zum Zitat Griffiths JR, Glickson JD. Monitoring pharmacokinetics of anticancer drags: non-invasive investigation using magnetic resonance spectroscopy. Adv Drag Deliv Rev 2000 Mar; 41(1): 75–89 Griffiths JR, Glickson JD. Monitoring pharmacokinetics of anticancer drags: non-invasive investigation using magnetic resonance spectroscopy. Adv Drag Deliv Rev 2000 Mar; 41(1): 75–89
92.
Zurück zum Zitat Dain JG, Collins JM, Robinson WT. A regulatory and industrial perspective of the use of carbon-14 and tritium isotopes in human ADME studies. Pharm Res 1994 Jun; 11(6): 925–8PubMed Dain JG, Collins JM, Robinson WT. A regulatory and industrial perspective of the use of carbon-14 and tritium isotopes in human ADME studies. Pharm Res 1994 Jun; 11(6): 925–8PubMed
93.
Zurück zum Zitat Barker J, Gamer RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom 1999; 13(4): 285–93PubMed Barker J, Gamer RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom 1999; 13(4): 285–93PubMed
94.
Zurück zum Zitat Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drag Discov 2003 Mar; 2(3): 233–40 Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drag Discov 2003 Mar; 2(3): 233–40
95.
Zurück zum Zitat Gurney H. Dose calculation of anticancer drags: a review of the current practice and introduction of an alternative. J Clin Oncol 1996 Sep; 14(9): 2590–611PubMed Gurney H. Dose calculation of anticancer drags: a review of the current practice and introduction of an alternative. J Clin Oncol 1996 Sep; 14(9): 2590–611PubMed
96.
Zurück zum Zitat Dent NJ. The inspection of drag metabolism and pharmacokinetic studies. Qual Assur 1992 Jun; 1(3): 230–6PubMed Dent NJ. The inspection of drag metabolism and pharmacokinetic studies. Qual Assur 1992 Jun; 1(3): 230–6PubMed
97.
Zurück zum Zitat Council of Europe. European Pharmacopoeia. Strasbourg: Council of Europe, 2002 Council of Europe. European Pharmacopoeia. Strasbourg: Council of Europe, 2002
98.
Zurück zum Zitat Goren MP, Wright RK, Pratt CB, et al. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986 Nov; II(8517): 1219–20 Goren MP, Wright RK, Pratt CB, et al. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986 Nov; II(8517): 1219–20
99.
Zurück zum Zitat Lind MJ, Margison JM, Cemy T, et al. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989 Feb; 49(3): 753–7PubMed Lind MJ, Margison JM, Cemy T, et al. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989 Feb; 49(3): 753–7PubMed
100.
Zurück zum Zitat Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001 Jan; 40(1): 41–62PubMed Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001 Jan; 40(1): 41–62PubMed
101.
Zurück zum Zitat Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia (PA): Williams & Wilkins, 1995 Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia (PA): Williams & Wilkins, 1995
102.
Zurück zum Zitat Oliverio VT, Walker MD, Hayes SL, et al. The physiological distribution of radioactive 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) in man [abstract]. Proc Am Assoc Cancer Res 1970; 11: 61 Oliverio VT, Walker MD, Hayes SL, et al. The physiological distribution of radioactive 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) in man [abstract]. Proc Am Assoc Cancer Res 1970; 11: 61
103.
Zurück zum Zitat Oliverio VT, Vietzke WM, Williams MK, et al. The absorption, distribution, excretion, and biotransformation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in animals. Cancer Res 1970 May; 30(5): 1330–7PubMed Oliverio VT, Vietzke WM, Williams MK, et al. The absorption, distribution, excretion, and biotransformation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in animals. Cancer Res 1970 May; 30(5): 1330–7PubMed
104.
Zurück zum Zitat Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittel Forschung 2001 Sep; 51(9): 699–725PubMed Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittel Forschung 2001 Sep; 51(9): 699–725PubMed
105.
Zurück zum Zitat Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 2004 May; 21(5): 719–35PubMed Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 2004 May; 21(5): 719–35PubMed
106.
Zurück zum Zitat Hirom PC, Millburn P, Smith RL, et al. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 1972 Oct; 129(5): 1071–7PubMed Hirom PC, Millburn P, Smith RL, et al. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 1972 Oct; 129(5): 1071–7PubMed
107.
Zurück zum Zitat Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 2000 Dec; 39(6): 429–43PubMed Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 2000 Dec; 39(6): 429–43PubMed
108.
Zurück zum Zitat Urien S, Bastian G, Lucas C, et al. Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets: usefulness of an erythrocyte partitioning technique. Invest New Drugs 1992 Nov; 10(4): 263–8PubMed Urien S, Bastian G, Lucas C, et al. Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets: usefulness of an erythrocyte partitioning technique. Invest New Drugs 1992 Nov; 10(4): 263–8PubMed
109.
Zurück zum Zitat Malingre MM, Schellens JHM, van Tellingen O, et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anticancer Drugs 2000 Nov; 11(10): 813–20PubMed Malingre MM, Schellens JHM, van Tellingen O, et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anticancer Drugs 2000 Nov; 11(10): 813–20PubMed
110.
Zurück zum Zitat Hardman JG, Limbird LE, editors. Goodman & Gilmans the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001 Hardman JG, Limbird LE, editors. Goodman & Gilmans the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001
111.
Zurück zum Zitat Rosenborg J, Larsson P, Tegner K, et al. Mass balance and metabolism of [(3)H]formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. Drug Metab Dispos 1999 Oct; 27(10): 1104–16PubMed Rosenborg J, Larsson P, Tegner K, et al. Mass balance and metabolism of [(3)H]formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. Drug Metab Dispos 1999 Oct; 27(10): 1104–16PubMed
112.
Zurück zum Zitat Lappin G, Garner RC. Ultra-sensitive detection of radiolabeled drugs and their metabolites using accelerator mass spectrometry. In: Wilson I, editor. Handbook of analytical separations. Amsterdam: Elsevier, 2003 Lappin G, Garner RC. Ultra-sensitive detection of radiolabeled drugs and their metabolites using accelerator mass spectrometry. In: Wilson I, editor. Handbook of analytical separations. Amsterdam: Elsevier, 2003
113.
Zurück zum Zitat Lappin G, Garner RC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem 2004 Jan; 378(2): 356–64PubMed Lappin G, Garner RC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem 2004 Jan; 378(2): 356–64PubMed
114.
Zurück zum Zitat Garner RC. Accelerator mass spectrometry in pharmaceutical research and development: a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000 Sep; 1(2): 205–13PubMed Garner RC. Accelerator mass spectrometry in pharmaceutical research and development: a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000 Sep; 1(2): 205–13PubMed
115.
Zurück zum Zitat Garner RC. The role of DNA adducts in chemical carcinogenesis. Mutat Res 1998 Jun; 402(1–2): 67–75PubMed Garner RC. The role of DNA adducts in chemical carcinogenesis. Mutat Res 1998 Jun; 402(1–2): 67–75PubMed
116.
Zurück zum Zitat Lightfoot TJ, Coxhead JM, Cupid BC, et al. Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene. Mutat Res 2000 Dec; 472(1–2): 119–27PubMed Lightfoot TJ, Coxhead JM, Cupid BC, et al. Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene. Mutat Res 2000 Dec; 472(1–2): 119–27PubMed
117.
Zurück zum Zitat Mauthe RJ, Dingley KH, Leveson SH, et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int J Cancer 1999 Feb; 80(4): 539–45PubMed Mauthe RJ, Dingley KH, Leveson SH, et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int J Cancer 1999 Feb; 80(4): 539–45PubMed
118.
Zurück zum Zitat Garner RC, Barker J, Flavell C, et al. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 2000 Dec; 24(2): 197–209PubMed Garner RC, Barker J, Flavell C, et al. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 2000 Dec; 24(2): 197–209PubMed
119.
Zurück zum Zitat Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 1992; 34(3): 344–50 Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 1992; 34(3): 344–50
Metadaten
Titel
Mass Balance Studies, with a Focus on Anticancer Drugs
verfasst von
Dr Jan H. Beumer
Jos H. Beijnen
Jan H. M. Schellens
Publikationsdatum
01.01.2006
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 1/2006
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200645010-00003

Weitere Artikel der Ausgabe 1/2006

Clinical Pharmacokinetics 1/2006 Zur Ausgabe

Original Research Article

Compliance-Guided Therapy